An overview of the Greek pharmaceutical market

Kontozamanis, Vassilis; Mantzouneas, E.; Stoforos, Chrysostomos

doi:10.1007/s10198-003-0206-1

Cited by 13 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Official sources suggest that the total share of parallel imports was almost 20% of the UK market, 14% of the Dutch market, 10% of the Danish and Swedish markets, and 7% of the German market in 2002. By contrast, parallel exports represented 16.7% and nearly 22% of the Greek market in 2000 and 2002 respectively according to official estimates (Kontozamanis et al, 2003). Price fixing and the concomitant price rigidity imply that price equalization or approximation from parallel trade as predicted by the theory of arbitrage are not occurring.…”

Section: Stylized Factsmentioning

confidence: 95%

Pharmaceutical parallel trade in Europe: stakeholder and competition effects

2005

View full text Add to dashboard Cite

"Pharmaceutical parallel trade in the European Union is a large and growing phenomenon, and hope has been expressed that it has the potential to reduce prices paid by health insurance and consumers and substantially to raise overall welfare. In this paper we examine the phenomenon empirically, using data on prices and volumes of individual imported products. We have found that the gains from parallel trade accrue mostly to the distribution chain rather than to health insurance and consumers. This is because in destination countries parallel traded drugs are priced just below originally sourced drugs. We also test to see whether parallel trade has a competition impact on prices in destination countries and find that it does not. Such competition effects as there are in pharmaceuticals come mainly from the presence of generics. Accordingly, instead of a convergence to the bottom in EU pharmaceutical prices, the evidence points at 'convergence to the top'. This is explained by the fact that drug prices are subjected to regulation in individual countries, and by the limited incentives of purchasers to respond to price differentials." Copyright � CEPR, CES, MSH, 2005.

show abstract

Section: Stylized Factsmentioning

confidence: 95%

Pharmaceutical parallel trade in Europe: stakeholder and competition effects

2005

View full text Add to dashboard Cite

show abstract

“…1). Between 1997 and 1998 there was a 11.9% decrease in real drug expenditures, which was mainly attributable to the new pricing policy that fixed prices of imported products at the lowest price in the EU but also to the fact that from July 1996 to September 1997, due to absence of pricing decisions, no new medicines were licensed for reimbursement [36].…”

Section: Level and Trend In Pharmaceutical Expendituresmentioning

confidence: 99%

The impotence of price controls: Failed attempts to constrain pharmaceutical expenditures in Greece

Lambrelli

O’Donnell

2011

Health Policy

View full text Add to dashboard Cite

“…The results also imply that the current pharmaceutical policies are in favor of imports, as the slope of the import and domestic production lines illustrate. The rise in Iranian pharmaceutical expenditure is expected to continue at a significant, even higher rate than expected from developing countries, based on factors mentioned above and the deliberate deficiencies of pharmaceutical policy [12,13]. Medicines are regarded as both public and industry goods.…”

Section: Discussionmentioning

confidence: 99%

Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries

et al. 2013

View full text Add to dashboard Cite

BackgroundSo far, no detailed study of the Iranian pharmaceutical market has been conducted, and only a few studies have analyzed medicine consumption and expenditure in Iran. Pharmaceutical market trend analysis remains one of the most useful instruments to evaluate the pharmaceutical systems efficiency. An increase in imports of medicines, and a simultaneous decrease in domestic production prompted us to investigate the pharmaceutical expenditure structure. On the other hand, analyzing statistics provides a suitable method to assess the outcomes of national pharmaceutical policies and regulations.MethodsThis is a descriptive and cross-sectional study which investigates the Iranian pharmaceutical market over a 13-year period (1997–2010). This study used the Iranian pharmaceutical statistical datasheet published by the Iranian Ministry of Health. Systematic searches of the relevant Persian and English research literature were made. In addition, official government documents were analyzed as sources of both data and detailed statements of policy.ResultsAnalysis of the Iranian pharmaceutical market in the 13-year period shows that medicine consumption sales value growth has been 28.38% annually. Determination of domestic production and import reveals that 9.3% and 42.3% annual growth, respectively, have been experienced.ConclusionsThe Iranian pharmaceutical market has undergone great growth in comparison with developing countries and the pharmerging group, and the market is expanding quickly while a major share goes to biotechnology drugs, which implies the need to commercialization activities in novel fields like pharmaceutical biotechnology. This market expansion has been in favor of imported medicine in sales terms, caused by the reinforcement of suspicious policies of policy makers that necessitates fundamental rearrangements.

show abstract

An overview of the Greek pharmaceutical market

Cited by 13 publications

References 2 publications

Pharmaceutical parallel trade in Europe: stakeholder and competition effects

Pharmaceutical parallel trade in Europe: stakeholder and competition effects

The impotence of price controls: Failed attempts to constrain pharmaceutical expenditures in Greece

Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries

Contact Info

Product

Resources

About